Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 2 , Pages 210-213 , April 2010

Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy

  • Keon Wook Kang, PhD

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • ,
  • Myung-Kwan Chun, PhD

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • ,
  • Ok Kim, MS

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • ,
  • Robhash Kusam Subedi, MPharm

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • ,
  • Sang-Gun Ahn, PhD

      Affiliations

    • Department of Pathology, College of Dentistry, Chosun University, Gwangju, South Korea
    • ,
  • Jung-Hoon Yoon, PhD

      Affiliations

    • Department of Pathology, College of Dentistry, Chosun University, Gwangju, South Korea
    • ,
  • Hoo-Kyun Choi, PhD

      Affiliations

    • BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
    • Research Center for Resistant Cells, Chosun University, Gwangju, South Korea
    • Corresponding Author InformationCorresponding author: College of Pharmacy, Chosun University, 375 Seosuk- dong, Dong-gu, Gwangju 501-759, South Korea.

Received 16 September 2009 ,Accepted 18 December 2009.

References 

  1. Bolhuis H, Veen HW, Poolman B, Driessen AJM, Konings WN. Mechanism of multidrug transporters. FEMS Microbiol Rev. 1997;21:55–84
  2. Stouch TR, Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Del Rev. 2002;54:315–328
  3. Consoli U, Priebe W, Ling YH, Mahadevia R, Griffin M, Zhao S, et al. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood. 1996;88:633–644
  4. Lyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect form tumor targeting. Drug Discov Today. 2006;11:812–818
  5. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel. 2000;65:271–284
  6. Müller RH, Madar K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177
  7. Kim BD, Na K, Choi HK. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur J Pharm Sci. 2005;24:199–205
  8. Chawla JS, Amiji MM. Biodegradable poly(x-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm. 2002;249:127–138
  9. Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci. 2009;37:508–513
  10. Han CY, Cho KB, Choi HS, Han HK, Kang KW. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis. 2008;29:1837–1844
  11. Simon SM. Role of organelle pH in tumor cell biology and drug resistance. Drug Discov Today. 1999;4:32–38
  12. Scovassi AI, Poirier GG. Poly(ADP-ribosylation) and apoptosis. Mol Cell Biochem. 1999;199:125–137

 This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science and Technology (MEST) through the Research Center for Resistant Cells (R13-2003-009).

PII: S1549-9634(10)00006-7

doi: 10.1016/j.nano.2009.12.006

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 2 , Pages 210-213 , April 2010

Article Tools

* Image Usage & Resolution